Naratriptan
ناراتریپتان
🧠 Nervous SystemTriptan (5-HT1B/1D agonist)
Market / country: 🇺🇸 USA
Amerge (US)
🧮 Dose calculator
Acute migraine attack · Regimen source: FDA Naratriptan · 2.1
- • If it returns or partial response: repeat once after 4 h; max 5 mg in 24 h. Mild/moderate renal or hepatic impairment: start 1 mg, max 2.5 mg/day. FDA Naratriptan · 2.1FDA Naratriptan · 2.2FDA Naratriptan · 2.3
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic/basilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity. FDA Naratriptan · 4
- ⛔ Severe renal impairment (CrCl <15) or severe hepatic impairment (Child-Pugh C). FDA Naratriptan · 2.2FDA Naratriptan · 2.3
Warnings
- • Myocardial ischaemia and infarction; arrhythmias; chest/throat/jaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure. FDA Naratriptan · 5
Renal adjustment
- • eGFR < 15: CrCl <15: contraindicated. FDA Naratriptan · 2.2
Formulations
- 2.5 mg tablet — tablet 🇺🇸 USA FDA Naratriptan · 3
- 1 mg tablet — tablet 🇺🇸 USA FDA Naratriptan · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Naratriptan · 8.1
“Risk Summary There are no adequate data on the developmental risk associated with use of naratriptan tablets in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Naratriptan · 8.2
“Risk Summary There are no data on the presence of naratriptan in human milk, the effects of naratriptan on the breastfed infant, or the effects of naratriptan on milk production.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Naratriptan · 8.4
“Safety and effectiveness in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Naratriptan · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA091441
- DailyMed (FDA label)FDA Naratriptan
- MedlinePlus (NIH)Naratriptan
- WHO ATC/DDDN02CC02
- Darooyab (Iran)Naratriptan
🇮🇷 Registered in Iran Darooyab · G-860/Naratriptan
Dosage forms with Iranian generic codes, per Darooyab.
- 13612 · NARATRIPTAN 2.5MG TAB · قرص ناراتریپتان ۲٫۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Naratriptan · 3FDA Naratriptan · 2.1FDA Naratriptan · 2.2FDA Naratriptan · 2.3FDA Naratriptan · 4FDA Naratriptan · 5FDA Naratriptan · SPL approval / marketing categoryFDA Naratriptan · 8.1FDA Naratriptan · 8.2FDA Naratriptan · 8.4FDA Naratriptan · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-860/Naratriptan
- Clinical review⚠ Unverified